Previous investigations underscored the high incidence of PD-L1 expression in oral squamous cell carcinoma patients, with a positive rate reaching 87.88%, thus indicating the potential benefits of immunotherapy in this patient subset (20). This evidence concerns the gene CD274 and oral cavity squamous cell carcinoma.